Cancer Epigenetic Biomarkers in Liquid Biopsy for High Incidence Malignancies

Data de publicació: 16/06/2021 Data Ahead of Print: 16/06/2021

Autors de IIS La Fe

Cora Palanca Ballester

Autor
Juan Sandoval Del Amor

Autor

Autors aliens a IIS La Fe

Rodriguez-Casanova, Aitor
Torres, Susana
Calabuig-Farinas, Silvia
Exposito, Francisco
Serrano, Diego
Redin, Esther
Valencia, Karmele
Jantus-Lewintre, Eloisa
Diaz-Lagares, Angel
Montuenga, Luis
Calvo, Alfonso

Grups d'Investigació

Unidad de Biomarcadores y Medicina de Precisión (UBYMP)

Leader

Agustín Lahoz Rodríguez

Abstract

Early alterations in cancer include the deregulation of epigenetic events such as changes in DNA methylation and abnormal levels of non-coding (nc)RNAs. Although these changes can be identified in tumors, alternative sources of samples may offer advantages over tissue biopsies. Because tumors shed DNA, RNA, and proteins, biological fluids containing these molecules can accurately reflect alterations found in cancer cells, not only coming from the primary tumor, but also from metastasis and from the tumor microenvironment (TME). Depending on the type of cancer, biological fluids encompass blood, urine, cerebrospinal fluid, and saliva, among others. Such samples are named with the general term "liquid biopsy" (LB). With the advent of ultrasensitive technologies during the last decade, the identification of actionable genetic alterations (i.e., mutations) in LB is a common practice to decide whether or not targeted therapy should be applied. Likewise, the analysis of global or specific epigenetic alterations may also be important as biomarkers for diagnosis, prognosis, and even for cancer drug response. Several commercial kits that assess the DNA promoter methylation of single genes or gene sets are available, with some of them being tested as biomarkers for diagnosis in clinical trials. From the tumors with highest incidence, we can stress the relevance of DNA methylation changes in the following genes found in LB: SHOX2 (for lung cancer); RASSF1A , RARB2 , and GSTP1 (for lung, breast, genitourinary and colon cancers); and SEPT9 (for colon cancer). Moreover, multi-cancer high-throughput methylation-based tests are now commercially available. Increased levels of the microRNA miR21 and several miRNA- and long ncRNA-signatures can also be indicative biomarkers in LB. Therefore, epigenetic biomarkers are attractive and may have a clinical value in cancer. Nonetheless, validation, standardization, and demonstration of an added value over the common clinical practice are issues needed to be addressed in the transfer of this knowledge from "bench to bedside".

Dades de la publicació

ISSN/ISSNe:: 2072-6694, 2072-6694
Tipus:: Article
Pàgines:: -
DOI:: 10.3390/cancers13123016
PubMed:: 34208598
Factor d'Impacte:: 1,349 SCImago ℠
Quartil:: Q1 SCImago ℠

Documents

No hi ha documents

Mètriques

Filiacions

Palanca-Ballester, Cora:: Instituto de Investigación. 1 Biomarkers and Precision Medicine (UBMP) and Epigenomics Unit, IIS, La Fe, 46026 Valencia, Spain.
Rodriguez-Casanova, Aitor:: 2 Cancer Epigenomics, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706 Santiago de Compostela, Spain.

3 Roche-CHUS Joint Unit, Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), 15706 Santiago de Compostela, Spain.
Torres, Susana:: 4 CIBERONC, ISCIII, 28029 Madrid, Spain.

5 Molecular Oncology Laboratory, Fundación Hospital General Universitario de Valencia, 46014 Valencia, Spain.

6 TRIAL Mixed Unit, Centro de Investigación Príncipe Felipe-Fundación para la Investigación del Hospital General Universitario de Valencia, 46014 Valencia, Spain.
Calabuig-Farinas, Silvia:: 4 CIBERONC, ISCIII, 28029 Madrid, Spain.

5 Molecular Oncology Laboratory, Fundación Hospital General Universitario de Valencia, 46014 Valencia, Spain.

6 TRIAL Mixed Unit, Centro de Investigación Príncipe Felipe-Fundación para la Investigación del Hospital General Universitario de Valencia, 46014 Valencia, Spain.

7 Department of Pathology, Universitat de València, 46010 Valencia, Spain.
Exposito, Francisco:: 4 CIBERONC, ISCIII, 28029 Madrid, Spain.

8 DISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), 31008 Pamplona, Spain.

9 Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, 31008 Pamplona, Spain.
Serrano, Diego:: 8 DISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), 31008 Pamplona, Spain.

9 Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, 31008 Pamplona, Spain.
Redin, Esther:: 4 CIBERONC, ISCIII, 28029 Madrid, Spain.

8 DISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), 31008 Pamplona, Spain.

9 Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, 31008 Pamplona, Spain.
Valencia, Karmele:: 4 CIBERONC, ISCIII, 28029 Madrid, Spain.

8 DISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), 31008 Pamplona, Spain.

10 Department of Biochemistry and Genetics, School of Sciences, University of Navarra, 31008 Pamplona, Spain.
Jantus-Lewintre, Eloisa:: 4 CIBERONC, ISCIII, 28029 Madrid, Spain.

5 Molecular Oncology Laboratory, Fundación Hospital General Universitario de Valencia, 46014 Valencia, Spain.

6 TRIAL Mixed Unit, Centro de Investigación Príncipe Felipe-Fundación para la Investigación del Hospital General Universitario de Valencia, 46014 Valencia, Spain.

11 Department of Biotechnology, Universitat Politècnica de València, 46022 Valencia, Spain.
Diaz-Lagares, Angel:: 2 Cancer Epigenomics, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706 Santiago de Compostela, Spain.

4 CIBERONC, ISCIII, 28029 Madrid, Spain.
Montuenga, Luis:: 4 CIBERONC, ISCIII, 28029 Madrid, Spain.

8 DISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), 31008 Pamplona, Spain.

9 Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, 31008 Pamplona, Spain.
Sandoval, Juan:: Instituto de Investigación. 1 Biomarkers and Precision Medicine (UBMP) and Epigenomics Unit, IIS, La Fe, 46026 Valencia, Spain.
Calvo, Alfonso:: 4 CIBERONC, ISCIII, 28029 Madrid, Spain.

8 DISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), 31008 Pamplona, Spain.

9 Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, 31008 Pamplona, Spain.